{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T09:43:55Z","timestamp":1779183835751,"version":"3.51.4"},"reference-count":54,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,2,10]],"date-time":"2021-02-10T00:00:00Z","timestamp":1612915200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100002428","name":"Austrian Science Fund","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002428","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:p><jats:bold>Background:<\/jats:bold> SARS-Cov2 has raised concerns among dermatologists regarding psoriasis and its respective treatments. Comorbidities, which induce the expression of the proprotease furin have been associated with severe course of COVID-19. Furin and angiotensin converting enzyme 2 (ACE2) play a major role in viral host cell entry of SARS-Cov2.<\/jats:p><jats:p><jats:bold>Objective:<\/jats:bold> To evaluate mRNA expression of Furin and ACE2 from blood cells in psoriasis patients, and whether systemic or topical treatment reduces expression levels.<\/jats:p><jats:p><jats:bold>Methods:<\/jats:bold> This observational translational study analyzed blood samples from patients from a clinical trial and samples retrieved from the biobank of the Psoriasis Registry Austria (PsoRA). Furin and ACE2 expression levels were analyzed prior to as well as 3 and 12\u201324 months after start of biologic treatment with either ustekinumab or secukinumab. Additionally, the study analyzed expression levels prior to, 6 days after start of dithranol treatment and 4\u20136 weeks after end of dithranol treatment.<\/jats:p><jats:p><jats:bold>Results:<\/jats:bold> Furin mRNA expression was significantly increased at baseline in the biologic (4.9 \u00b1 2.6 fold, <jats:italic>p<\/jats:italic> &amp;lt; 0.0001) and in the dithranol group (2.7 \u00b1 1.4 fold, <jats:italic>p<\/jats:italic> &amp;lt; 0.001) compared to controls. There was a trend for arthritis patients to express more furin than patients with psoriatic skin involvement only (5.26 \u00b1 2.30 vs. 3.48 \u00b1 2.27, <jats:italic>p<\/jats:italic> = 0.078). Analyzing furin mRNA expression after treatment initiation with secukinumab or ustekinumab revealed a normalization of levels after 3 and 12 to 24 months. Similar findings were obtained for patients treated with dithranol, with significantly decreased expression levels 6 days after start of dithranol treatment and also at follow-up, (4\u20136 weeks after dithranol treatment had been terminated). ACE2 expression levels did not differ from controls at any timepoint, regardless of biologic or topical treatment.<\/jats:p><jats:p><jats:bold>Conclusion:<\/jats:bold> Significantly overexpressed levels of furin were observed in untreated patients, and, thus, these patients may be at risk for infection and a severe course of COVID-19. However, the data indicate that successful therapeutic intervention in psoriasis, by systemic biologic or topical treatment, can efficiently reduce furin levels in blood cells, possibly limiting the risk of psoriasis patients for a severe COVID-19 course.<\/jats:p><jats:p><jats:bold>Clinical Trial Registration:<\/jats:bold><jats:ext-link>ClinicalTrials.gov<\/jats:ext-link>, identifier NCT02752672.<\/jats:p>","DOI":"10.3389\/fmed.2021.624462","type":"journal-article","created":{"date-parts":[[2021,2,10]],"date-time":"2021-02-10T16:14:01Z","timestamp":1612973641000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":5,"title":["Furin Expression in Patients With Psoriasis\u2014A Patient Cohort Endangered to SARS-COV2?"],"prefix":"10.3389","volume":"8","author":[{"given":"Thomas","family":"Graier","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicole","family":"Golob-Schwarzl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wolfgang","family":"Weger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Theresa","family":"Benezeder","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Clemens","family":"Painsi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wolfgang","family":"Salmhofer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Wolf","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2021,2,10]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"2019","DOI":"10.1016\/s2468-1253(20)30076-5","article-title":"Implications of COVID-19 for patients with pre-existing digestive diseases","volume":"2019","author":"Mao","year":"2020","journal-title":"Lancet Gastroenterol Hepatol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.1016\/j.jaad.2020.03.031","article-title":"Should biologics for psoriasis be interrupted in the era of COVID-19?","volume":"82","author":"Lebwohl","year":"2020","journal-title":"J Am Acad Dermatol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"e13298","DOI":"10.1111\/dth.13298","article-title":"COVID-19 and psoriasis: is it time to limit treatment with immunosuppressants? A call for action","volume":"33","author":"Conforti","year":"2020","journal-title":"Dermatol Ther."},{"key":"B4","doi-asserted-by":"publisher","first-page":"1726","DOI":"10.1016\/j.jid.2018.01.039","article-title":"Risk of serious infection, opportunistic infection, and herpes zoster among patients with psoriasis in the United Kingdom","volume":"138","author":"Takeshita","year":"2018","journal-title":"J Invest Dermatol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1111\/bjd.19052","article-title":"Risk of hospitalisation and death due to infection in people with psoriasis: a population-based cohort study using the clinical practice research datalink","volume":"184","author":"Yiu","year":"2020","journal-title":"Br J Dermatol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"e13858","DOI":"10.1111\/dth.13858","article-title":"Psoriasis and COVID-19 : a narrative review with treatment considerations","volume":"33","author":"Faruk","year":"2020","journal-title":"Dermatol Ther."},{"key":"B7","doi-asserted-by":"publisher","first-page":"e13434","DOI":"10.1111\/dth.13434","article-title":"COVID-19 and psoriasis : should we fear for patients treated with biologics?","volume":"33","author":"Amerio","year":"2020","journal-title":"Dermatol Ther."},{"key":"B8","doi-asserted-by":"publisher","first-page":"e13687","DOI":"10.1111\/dth.13687","article-title":"Considerations for safety in the use of systemic medications for psoriasis and atopic dermatitis during the COVID-19 pandemic","volume":"33","author":"Ricardo","year":"2020","journal-title":"Dermatol Ther."},{"key":"B9","doi-asserted-by":"publisher","first-page":"e676","DOI":"10.1111\/jdv.16761","article-title":"Systemic or biologic treatment in psoriasis patients does not increase the risk of a severe form of COVID-19","volume":"34","author":"Fougerousse","year":"2020","journal-title":"J Eur Acad Dermatology Venereol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1111\/bjd.19158","article-title":"The impact of the COVID-19 pandemic on patients with chronic plaque psoriasis being treated with biological therapy: the Northern Italy experience","volume":"183","author":"Gisondi","year":"2020","journal-title":"Br J Dermatol."},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1080\/14712598.2021.1853698","article-title":"Characteristic of chronic plaque psoriasis patients treated with biologics in italy during the COVID-19 pandemic: risk analysis from the PSO-BIO-COVID observational study","author":"Talamonti","year":"2020","journal-title":"Expert Opin Biol Ther."},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2020.10.032","article-title":"Incidence rates of hospitalization and death from COVID-19 in patients with psoriasis receiving biological treatment: a Northern Italy experience","author":"Paolo","year":"2020","journal-title":"J Allergy Clin Immunol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1136\/annrheumdis-2020-217871","article-title":"Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease : data from the COVID-19 Global Rheumatology Alliance physician\u2014reported registry","volume":"79","author":"Gianfrancesco","year":"2020","journal-title":"Ann Rheum Dis."},{"key":"B14","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/S0140-6736(20)30628-0","article-title":"COVID-19: consider cytokine storm syndromes and immunosuppression","volume":"6736","author":"Mehta","year":"2020","journal-title":"Lancet (London, England)."},{"key":"B15","doi-asserted-by":"publisher","first-page":"H1080","DOI":"10.1152\/ajpheart.00215.2020","article-title":"Angiotensin converting enzyme 2\u2014an ally or a Trojan horse? Implications to SARS-CoV-2 -related cardiovascular complications","volume":"318","author":"Abassi","year":"2020","journal-title":"Am J Physiol Heart Circ Physiol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"L1020","DOI":"10.1152\/ajplung.00097.2020","article-title":"Covid-19 infection and mortality\u2014a physiologist's perspective enlightening clinical features and plausible interventional strategies","volume":"318","author":"Abassi","year":"2020","journal-title":"Am J Physiol Lung Cell Mol Physiol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1111\/joim.12783","article-title":"Plasma levels of the proprotein convertase furin and incidence of diabetes and mortality","volume":"284","author":"Fernandez","year":"2018","journal-title":"J Intern Med."},{"key":"B18","doi-asserted-by":"publisher","first-page":"110917","DOI":"10.1016\/j.mce.2020.110917","article-title":"Irisin modulates genes associated with severe coronavirus disease (COVID-19) outcome in human subcutaneous adipocytes cell culture","volume":"515","author":"de Oliveira","year":"2020","journal-title":"Mol Cell Endocrinol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1016\/j.atherosclerosis.2011.08.011","article-title":"Proprotein convertases in human atherosclerotic plaques: The overexpression of FURIN and its substrate cytokines BAFF and APRIL","volume":"219","author":"Turpeinen","year":"2011","journal-title":"Atherosclerosis."},{"key":"B20","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/B978-0-12-407680-8.00001-4","article-title":"BNP molecular forms and processing by the cardiac serine protease corin","volume":"61","author":"Ichiki","year":"2013","journal-title":"Adv Clin Chem."},{"key":"B21","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1189\/jlb.2a0514-257rr","article-title":"Proprotein convertase FURIN regulates T cell receptor-induced transactivation","volume":"98","author":"Ortutay","year":"2015","journal-title":"J Leukoc Biol."},{"key":"B22","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1182\/blood-2005-09-3824","article-title":"Proprotein convertase furin is preferentially expressed in T helper 1 cells and regulates interferon gamma","volume":"108","author":"Pesu","year":"2006","journal-title":"Blood."},{"key":"B23","doi-asserted-by":"publisher","first-page":"2612","DOI":"10.4049\/jimmunol.1700808","article-title":"STAT6 and furin are successive triggers for the production of TGF-\u03b2 by T cells","volume":"201","author":"Li","year":"2018","journal-title":"J Immunol."},{"key":"B24","doi-asserted-by":"publisher","first-page":"54392","DOI":"10.18632\/oncotarget.11106","article-title":"Myeloid cell expressed proprotein convertase FURIN attenuates inflammation","volume":"7","author":"Cordova","year":"2016","journal-title":"Oncotarget."},{"key":"B25","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1080\/03009742.2018.1520294","article-title":"Increased expression of the proprotein convertase enzyme FURIN in rheumatoid arthritis","volume":"48","author":"Valli","year":"2019","journal-title":"Scand J Rheumatol."},{"key":"B26","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1111\/sji.12386","article-title":"The plasma level of proprotein convertase FURIN in patients with suspected infection in the emergency room: a prospective cohort study","volume":"82","author":"Ranta","year":"2015","journal-title":"Scand J Immunol."},{"key":"B27","doi-asserted-by":"publisher","first-page":"2102","DOI":"10.1021\/acs.jproteome.5b00905","article-title":"Antibody-array-based proteomic screening of serum markers in systemic lupus erythematosus: a discovery study","volume":"15","author":"Wu","year":"2016","journal-title":"J Proteome Res."},{"key":"B28","first-page":"S47","article-title":"Proprotein convertase enzyme FURIN is upregulated in primary Sj\u00f6gren's syndrome","volume":"36","author":"Ranta","year":"2018","journal-title":"Clin Exp Rheumatol."},{"key":"B29","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1124\/pr.116.012989","article-title":"The proprotein convertases in hypercholesterolemia and cardiovascular diseases: emphasis on proprotein convertase subtilisin\/Kexin 9","volume":"69","author":"Seidah","year":"2017","journal-title":"Pharmacol Rev."},{"key":"B30","doi-asserted-by":"publisher","first-page":"21992","DOI":"10.1074\/jbc.M111.332643","article-title":"Highly potent inhibitors of proprotein convertase furin as potential drugs for treatment of infectious diseases","volume":"287","author":"Becker","year":"2012","journal-title":"J Biol Chem."},{"key":"B31","doi-asserted-by":"publisher","first-page":"20847","DOI":"10.1074\/jbc.M703847200","article-title":"Targeting host cell furin proprotein convertases as a therapeutic strategy against bacterial toxins and viral pathogens","volume":"282","author":"Shiryaev","year":"2007","journal-title":"J Biol Chem."},{"key":"B32","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.cub.2020.03.022","article-title":"Probable pangolin origin of 2019-nCoV associated with outbreak of COVID-19","volume":"30","author":"Zhang","year":"2020","journal-title":"Curr Biol."},{"key":"B33","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.cell.2020.02.058","article-title":"Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein","volume":"181","author":"Walls","year":"2020","journal-title":"Cell."},{"key":"B34","doi-asserted-by":"publisher","first-page":"109893","DOI":"10.1016\/j.mehy.2020.109893","article-title":"Expression of angiotensin-converting enzyme 2 and proteases in COVID-19 patients: a potential role of cellular FURIN in the pathogenesis of SARS-CoV-2","volume":"143","author":"Drak Alsibai","year":"2020","journal-title":"Med Hypotheses."},{"key":"B35","doi-asserted-by":"publisher","first-page":"3001","DOI":"10.1093\/eurheartj\/ehu381","article-title":"Post-transcriptional modification of pro-BNP in heart failure: is glycosylation and circulating furin key for cardiovascular homeostasis?","volume":"35","author":"Ichiki","year":"2014","journal-title":"Eur Heart J."},{"key":"B36","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1038\/nature07210","article-title":"T-cell-expressed proprotein convertase furin is essential for maintenance of peripheral immune tolerance","volume":"455","author":"Pesu","year":"2008","journal-title":"Nature."},{"key":"B37","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1093\/infdis\/jiv380","article-title":"Middle east respiratory syndrome coronavirus efficiently infects human primary t lymphocytes and activates the extrinsic and intrinsic apoptosis pathways","volume":"213","author":"Chu","year":"2016","journal-title":"J Infect Dis."},{"key":"B38","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fimmu.2020.00827","article-title":"Reduction and functional exhaustion of T cells in patients with coronavirus disease 2019 (COVID-19)","volume":"11","author":"Diao","year":"2020","journal-title":"Front Immunol."},{"key":"B39","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/S0140-6736(20)30566-3","article-title":"Articles clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China : a retrospective cohort study","volume":"6736","author":"Zhou","year":"2020","journal-title":"Lancet."},{"key":"B40","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1016\/S0140-6736(20)30183-5","article-title":"Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China","volume":"395","author":"Huang","year":"2020","journal-title":"Lancet."},{"key":"B41","doi-asserted-by":"publisher","first-page":"1","DOI":"10.15252\/embj.20105114","article-title":"SARS -CoV-2 receptor ACE 2 and TMPRSS 2 are primarily expressed in bronchial transient secretory cells","volume":"39","author":"Lukassen","year":"2020","journal-title":"EMBO J."},{"key":"B42","doi-asserted-by":"publisher","first-page":"428","DOI":"10.3390\/v12040428","article-title":"Molecular mechanism of evolution and human infection with SARS-CoV-2","volume":"12","author":"He","year":"2020","journal-title":"Viruses."},{"key":"B43","doi-asserted-by":"publisher","first-page":"e21","DOI":"10.1016\/S2213-2600(20)30116-8","article-title":"Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection?","volume":"8","author":"Fang","year":"2020","journal-title":"Lancet Respir Med."},{"key":"B44","doi-asserted-by":"publisher","first-page":"1477","DOI":"10.1007\/s11739-020-02500-2","article-title":"Neither ACEIs nor ARBs are associated with respiratory distress or mortality in COVID-19 results of a prospective study on a hospital-based cohort","volume":"15","author":"Anzola","year":"2020","journal-title":"Intern Emerg Med."},{"key":"B45","doi-asserted-by":"publisher","first-page":"1","DOI":"10.7554\/eLife.56991","article-title":"Dithranol targets keratinocytes, their crosstalk with neutrophils and inhibits the il-36 inflammatory loop in psoriasis","volume":"9","author":"Benezeder","year":"2020","journal-title":"Elife."},{"key":"B46","doi-asserted-by":"publisher","first-page":"96","DOI":"10.3389\/fimmu.2019.03096","article-title":"IL-17A in psoriasis and beyond: cardiovascular and metabolic implications","volume":"10","author":"von Stebut","year":"2020","journal-title":"Front Immunol."},{"key":"B47","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.1016\/j.jid.2018.10.042","article-title":"Impact of secukinumab on endothelial dysfunction and other cardiovascular disease parameters in psoriasis patients over 52 weeks","volume":"139","author":"von Stebut","year":"2019","journal-title":"J Invest Dermatol."},{"key":"B48","doi-asserted-by":"publisher","first-page":"e14516","DOI":"10.1111\/dth.14516","article-title":"Does therapy with biological drugs influence COVID-19 infection? Observational, monocentric prevalence study on the clinical and epidemiological data of psoriatic patients treated with biological drugs or with topical drugs alone","volume":"33","author":"Brazzelli","year":"2020","journal-title":"Dermatol Ther."},{"key":"B49","doi-asserted-by":"publisher","first-page":"2829","DOI":"10.1111\/all.14429","article-title":"Distribution of ACE2, CD147, CD26, and other SARS-CoV-2 associated molecules in tissues and immune cells in health and in asthma, COPD, obesity, hypertension, and COVID-19 risk factors","volume":"75","author":"Radzikowska","year":"2020","journal-title":"Allergy Eur J Allergy Clin Immunol."},{"key":"B50","doi-asserted-by":"publisher","first-page":"4383","DOI":"10.1007\/s11033-020-05478-4","article-title":"Expressions and significances of the angiotensin-converting enzyme 2 gene, the receptor of SARS-CoV-2 for COVID-19","volume":"47","author":"Fu","year":"2020","journal-title":"Mol Biol Rep."},{"key":"B51","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1186\/s40249-020-00662-x","article-title":"Expression of the SARS-CoV-2 cell receptor gene ACE2 in a wide variety of human tissues","volume":"9","author":"Li","year":"2020","journal-title":"Infect Dis Poverty."},{"key":"B52","doi-asserted-by":"publisher","first-page":"1416","DOI":"10.2337\/dc20-0643","article-title":"Exploring diseases\/traits and blood proteins causally related to expression of ACE2, the putative receptor of SARS-CoV-2: a mendelian randomization analysis highlights tentative relevance of diabetes-related traits","volume":"43","author":"Rao","year":"2020","journal-title":"Diabetes Care."},{"key":"B53","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1371\/journal.pone.0070542","article-title":"Proprotein convertase subtilisin\/kexin type 3 promotes adipose tissue-driven macrophage chemotaxis and is increased in obesity","volume":"8","author":"Kappert","year":"2013","journal-title":"PLoS ONE."},{"key":"B54","doi-asserted-by":"publisher","first-page":"148651","DOI":"10.1155\/2015\/148651","article-title":"Liver-specific inactivation of the proprotein convertase FURIN leads to increased hepatocellular carcinoma growth","volume":"2015","author":"Declercq","year":"2015","journal-title":"Biomed Res Int."}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2021.624462\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,2,10]],"date-time":"2021-02-10T16:14:06Z","timestamp":1612973646000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2021.624462\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,10]]},"references-count":54,"alternative-id":["10.3389\/fmed.2021.624462"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2021.624462","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,2,10]]},"article-number":"624462"}}